Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 2, 2008, Pages 309-313

  Choi, Hye Jin ^a   Cho, Byoung Chul ^a   Shin, Sang Joon ^a   Cheon, Seong Ha ^a   Jung, Jong Yul ^a   Chang, Joon ^b   Kim, Se Kyu ^b   Sohn, Joo Hyuk ^a   Kim, Joo Hang ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; IRINOTECAN; PLATINUM; TOPOTECAN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GENERAL WEAKNESS; HERPES ZOSTER; HUMAN; LEUKOPENIA; LUNG SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PNEUMONIA; PRIORITY JOURNAL; SALVAGE THERAPY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, SMALL CELL; COMBINED MODALITY THERAPY; ENDPOINT DETERMINATION; ETOPOSIDE; FEMALE; HEMATOLOGIC DISEASES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PATIENT COMPLIANCE; SALVAGE THERAPY; TOPOTECAN;

EID: 36349008662     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0505-9     Document Type: Article

References (21)

1. Clark R, Ihde DC (1998) Small-cell lung cancer: treatment progress and prospects. Oncology (Williston Park) 12:647-658 (discussion 661-663)
2. Albain KS, Crowley JJ, Hutchins L et al (1993) Predictors of survival following relapse or progression of small cell lung cancer. Southwest Oncology Group Study 8605 report and analysis of recurrent disease database. Cancer 72:1184-1191
3. O'Brien M, Ciuleanu T, Tsekov H et al (2006) Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 24:5441-5447
4. Von Pawel J, Schiller JH, Shepherd FA et al (1999) Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17:658-667
5. Mascaux C, Paesmans M, Berghmans T et al (2000) A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 30:23-36
6. Jonsson E, Fridborg H, Nygren P et al (1998) Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients. Eur J Clin Pharmacol 54:509-514
7. Kollmannsberger C, Mross K, Jakob A et al (1999) Topotecan-a novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology 56:1-12
8. Kim R, Hirabayashi N, Nishiyama M et al (1992) Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int J Cancer 50:760-766
9. Whitacre CM, Zborowska E, Gordon NH et al (1997) Topotecan increases topoisomerase II alpha levels and sensitivity to treatment with etoposide in schedule-dependent process. Cancer Res 57:1425-1428
10. Masuda N, Matsui K, Negoro S et al (1998) Combination of irinotecan and etoposide for treatment of refractory of relapsed small-cell lung cancer. J Clin Oncol 16(10):3329-3334
11. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
12. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10
13. Noda K, Nishiwaki Y, Kawahara M et al (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85-91
14. Sohn JH, Choi HJ, Chang J et al (2006) A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer. Lung Cancer 54:365-370
15. Calver L, Santos a, Valent A et al (2004) No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecan. Br J Cancer 91:1205-1212
16. Lokich J (2001) Phase I clinical trial of weekly combined topotecan and irinotean. Am J Clin Oncol 24(4):336-340
17. Rosti G, Bevilacqua G, Bidoli P et al (2006) Small cell lung cancer. Ann Oncol 17(Suppl 2):ii5-ii10
18. Shivayama T, Hotta K, Takigawa N, et al (2006) A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer. Lung Cancer 53:189-195
19. Reck M, Groth G, Buchholz E et al (2005) Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen. Lung Cancer 48:409-413
20. O'Neill P, Clark PI, Smith D et al (2001) A phase I trial of a 5-day schedule of intravenous topotecan and etoposide in previously untreated patients with small cell lung cancer. Oncology 61(Suppl 1):25-29
21. Eckardt JR (2004) Emerging role of weekly topotecan in recurrent small cell lung cancer. Oncologist 9(Suppl 6):25-32